Thasarat Sutabutr Vajaranant1, Roberta M Ray2, Louis R Pasquale3, Julie A Mares4, Robert Ritch5, Emily W Gower6, Mary N Haan7, Rebecca D Jackson8, Pauline M Maki9. 1. Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois, USA. Electronic address: thasarat@uic.edu. 2. Women's Health Initiative, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. 3. Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA; Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. 4. Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin, USA. 5. Einhorn Clinical Research Center, The New York Eye and Ear Infirmary of Mount Sinai, New York, New York, USA. 6. Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 7. Department of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, California, USA. 8. Center for Clinical and Translational Research, Ohio State University, Columbus, Ohio, USA. 9. Department of Psychiatry and Psychology, University of Illinois at Chicago, Chicago, Illinois, USA.
Abstract
PURPOSE: We conducted a secondary analysis of a randomized, placebo-controlled trial to test if hormone therapy (HT) altered the risk of open-angle glaucoma (OAG), and if the risk reduction varied by race. DESIGN: Secondary analysis of randomized controlled trial data. METHODS: We linked Medicare claims data to 25 535 women in the Women's Health Initiative. Women without a uterus were randomized to receive either oral conjugated equine estrogens (CEE 0.625 mg/day) or placebo, and women with a uterus receivedoral CEE and medroxyprogesterone acetate (CEE 0.625 mg/day + MPA 2.5 mg/day) or placebo. We used Cox proportional hazards models to calculate hazard ratios (HR) and 95% confidence interval. RESULTS: After exclusion of women with prevalent glaucoma or without claims for eye care provider visits, the final analysis included 8102 women (mean age = 68.5 ± 4.8 years). The OAG incidence was 7.6% (mean follow-up = 11.5 ± 5.2 years; mean HT duration = 4.4 ± 2.3 years). Increased age (P trend = .01) and African-American race (HR = 2.69, 95% CI = 2.13-3.42; white as a reference) were significant risk factors for incident OAG. We found no overall benefit of HT in reducing incident OAG (HR = 1.01, 95% CI = 0.79-1.29 in the CEE trial, and HR = 1.05, 95% CI = 0.85-1.29 in the CEE + MPA trial). However, race modified the relationship between CEE use and OAG risk (P interaction = .01), and risk was reduced in African-American women treated with CEE (HR = 0.49, 95% CI = 0.27-0.88), compared to placebo. Race did not modify the relation between CEE + MPA use and OAG risk (P interaction = .68). CONCLUSIONS: Analysis suggests that HT containing estrogen, but not a combination of estrogen and progesterone, reduces the risk of incident OAG among African-American women. Further investigation is needed.
RCT Entities:
PURPOSE: We conducted a secondary analysis of a randomized, placebo-controlled trial to test if hormone therapy (HT) altered the risk of open-angle glaucoma (OAG), and if the risk reduction varied by race. DESIGN: Secondary analysis of randomized controlled trial data. METHODS: We linked Medicare claims data to 25 535 women in the Women's Health Initiative. Women without a uterus were randomized to receive either oral conjugated equine estrogens (CEE 0.625 mg/day) or placebo, and women with a uterus received oral CEE and medroxyprogesterone acetate (CEE 0.625 mg/day + MPA 2.5 mg/day) or placebo. We used Cox proportional hazards models to calculate hazard ratios (HR) and 95% confidence interval. RESULTS: After exclusion of women with prevalent glaucoma or without claims for eye care provider visits, the final analysis included 8102 women (mean age = 68.5 ± 4.8 years). The OAG incidence was 7.6% (mean follow-up = 11.5 ± 5.2 years; mean HT duration = 4.4 ± 2.3 years). Increased age (P trend = .01) and African-American race (HR = 2.69, 95% CI = 2.13-3.42; white as a reference) were significant risk factors for incident OAG. We found no overall benefit of HT in reducing incident OAG (HR = 1.01, 95% CI = 0.79-1.29 in the CEE trial, and HR = 1.05, 95% CI = 0.85-1.29 in the CEE + MPA trial). However, race modified the relationship between CEE use and OAG risk (P interaction = .01), and risk was reduced in African-American women treated with CEE (HR = 0.49, 95% CI = 0.27-0.88), compared to placebo. Race did not modify the relation between CEE + MPA use and OAG risk (P interaction = .68). CONCLUSIONS: Analysis suggests that HT containing estrogen, but not a combination of estrogen and progesterone, reduces the risk of incident OAG among African-American women. Further investigation is needed.
Authors: Simone de Voogd; M Kamran Ikram; Roger C W Wolfs; Nomdo M Jansonius; Albert Hofman; Paulus T V M de Jong Journal: Ophthalmology Date: 2005-09 Impact factor: 12.079
Authors: Micheline C Deschênes; Denise Descovich; Michèle Moreau; Louis Granger; George A Kuchel; Tomi S Mikkola; Gordon H Fick; Sylvain Chemtob; Elvire Vaucher; Mark R Lesk Journal: Invest Ophthalmol Vis Sci Date: 2009-12-17 Impact factor: 4.799
Authors: Louis R Pasquale; Akiko Hanyuda; Ai Ren; Michael Giovingo; Scott H Greenstein; Clara Cousins; Thomas Patrianakos; Angelo P Tanna; Christopher Wanderling; William Norkett; Janey L Wiggs; Kelsey Green; Jae H Kang; Paul A Knepper Journal: Invest Ophthalmol Vis Sci Date: 2015-11 Impact factor: 4.799